InvestorsHub Logo
Followers 827
Posts 119484
Boards Moderated 15
Alias Born 09/05/2002

Re: pearsby09 post# 2546

Saturday, 02/25/2017 10:44:25 AM

Saturday, February 25, 2017 10:44:25 AM

Post# of 4859
GILD already has three TAF-based products on the market: Genvoya (a/k/a E/C/F/TAF) was approved in Nov 2015 as a replacement for Stribild (#msg-118275552); Odefsey (a/k/a R/F/TAF) was approved in Mar 2016 (#msg-120889707) as a replacement for Complera/Eviplera; Descovy (a/k/a F/TAF) was approved in Apr 2016 (#msg-121672266) as a replacement for Truvada.

(The above are the FDA approval dates. Approval dates in the EU and other jurisdictions vary.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News